How Is NSIP Differentiated From Fibrotic HP on HRCT?

Clinicians differentiate non-specific interstitial pneumonia (NSIP) from fibrotic hypersensitivity pneumonitis (fibrotic HP or fHP) by combining a detailed environmental exposure history, specific patterns on high-resolution CT (HRCT) scans, and subtle differences in lung biopsy samples ^[1][2].

The distinction can be challenging because NSIP is a specific pattern of lung inflammation and scarring that can happen on its own or result from other diseases, while fibrotic HP is a disease caused by inhaling an environmental trigger. No single test can easily tell them apart, as their features frequently overlap, and fibrotic HP can even directly mimic the NSIP pattern on scans and biopsies ^[3]. Therefore, doctors rely on a collaborative, multidisciplinary team approach to integrate all the clues and arrive at an accurate diagnosis ^[4][5].

The Role of Exposure History

In fibrotic HP, lung scarring is driven by an immune reaction to inhaling an environmental trigger—most commonly proteins from birds (like pet birds, pigeons, or down bedding), indoor mold, agricultural dusts, or occupational exposures ^[6][7]. Doctors use structured questionnaires to uncover hidden or forgotten exposures, because a routine history might miss them ^[8].

Blood tests checking for IgG or precipitins (specific antibodies) can show if your immune system has been exposed to certain antigens (triggers). However, a positive result only proves exposure, not that the trigger caused your lung disease ^[6][9]. Conversely, a negative blood test does not rule out fibrotic HP, because these panels cannot test for every possible environmental trigger in the world. Furthermore, even with thorough investigation, a significant portion of patients with a typical fibrotic HP CT pattern may never have a clear exposure identified ^[10].

NSIP is a pattern that can be secondary to connective tissue diseases (like rheumatoid arthritis or scleroderma), medication side effects, or other causes. When thorough evaluation finds no underlying cause, it is called idiopathic NSIP. However, because an exposure cannot always be found in patients who truly have fibrotic HP, an absent exposure does not automatically prove the diagnosis is NSIP ^[11].

Clues from High-Resolution CT (HRCT) Scans

HRCT scans provide critical clues by showing how the disease affects different parts of the lungs. The key differences often relate to how the disease affects the airways versus the deeper lung tissue. These features are supportive tendencies, not absolute rules:

• Airway involvement: Fibrotic HP typically affects the small airways. Signs like mosaic attenuation (patchy areas of different lung densities) and air trapping (air remaining stuck in the lungs when you exhale) suggest fibrotic HP ^[12]. Air trapping is best assessed when the CT scan includes images taken while you exhale (expiratory scans).
• Centrilobular nodules: These are tiny spots in the center of the lung’s functional units, which are common in fibrotic HP but rare in NSIP ^[13].
• Disease distribution: NSIP usually affects the lower parts of the lungs and may spare the area right at the edge of the lung (subpleural sparing) ^[14]. Fibrotic HP often involves the upper or middle parts of the lungs, or clusters around the airways (peribronchovascular distribution) ^[15][16].
• The Three-Density Pattern: Sometimes called the “headcheese sign,” this is a mix of normal-appearing lung, ground-glass opacity (hazy areas of inflammation), and trapped air. When correctly identified, it is highly suggestive of fibrotic HP ^[17].

Despite these clues, radiologic patterns can look very similar, and fibrotic HP can sometimes produce an imaging pattern identical to NSIP ^[3].

Lung Biopsy and Pathology Findings

A lung biopsy is not always required. A multidisciplinary team may reach a confident diagnosis based on history, imaging, and blood tests alone. When a biopsy is performed, pathologists look under a microscope for specific clues:

• Airway-centered features: Pathologists look for peribronchiolar fibrosis (scarring that centers around the small airways) and bridging fibrosis (scar tissue that bridges the gaps between airways or other lung structures). These findings favor fibrotic HP ^[2][18].
• Granulomas or giant cells: These are small clusters of immune cells reacting to an inhaled trigger. While their presence points strongly to fibrotic HP, they often disappear as the fibrosis becomes more advanced, meaning their absence does not rule out the disease ^[4][2].

In contrast, the NSIP pattern is characterized by relatively uniform inflammation and scarring throughout the lung tissue, without these airway-centered features ^[14]. However, pathology can be tricky because fibrotic HP can cause an NSIP-like pattern in some parts of the lung, and smaller biopsy samples—like a transbronchial biopsy (a small sample taken through a flexible tube in the airways)—might miss the key features that a larger surgical biopsy would show ^[3][19]. Pathologists must weigh the overall pattern rather than relying on a simple checklist.

The Importance of Multidisciplinary Discussion

Because findings overlap significantly, diagnosing the condition requires a multidisciplinary discussion (MDD). In an MDD, pulmonologists, radiologists, and pathologists review all of your information together. This collaborative approach is essential for interpreting conflicting clues, deciding if a biopsy is necessary, and reaching the most accurate diagnosis ^[20][5].

Even with expert review, some cases remain uncertain or unclassifiable. Making the best possible distinction is important because it guides your individualized care plan. In fibrotic HP, identifying and avoiding the environmental trigger is a central focus, though treatment may also include immune-suppressing or anti-fibrotic medications for progressive disease ^[21]. NSIP treatment depends heavily on whether it is idiopathic or secondary to another condition, often involving immune-suppressing medications ^[14]. Always consult your medical team before making major changes to your environment, medications, or living situation.